Quick Facts
As of FYE 10/31/12

Global Headquarters
Pleasanton, CA

Worldwide Employees
Approx. 7,800

Business Units
CooperVision
CooperSurgical

Industries
Vision care (contact lenses)
Women’s health (obstetrics, gynecology)

Websites
www.coopercos.com
www.coopervision.com
www.coopersurgical.com

Stock Information
(As of FYE 10/31/12)

Stock Symbol COO
Stock Exchange NYSE Euronext
Stock Price $95.95
Diluted Shares 49.2 million
Market Capitalization $4.6 billion

Financial Summary
(FY 2012 - Consolidated)

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$1.4 billion</td>
</tr>
<tr>
<td>GAAP Earnings Per Share</td>
<td>$5.05</td>
</tr>
<tr>
<td>Non-GAAP Earnings Per Share</td>
<td>$5.16</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>$230.4 million</td>
</tr>
</tbody>
</table>

(1) See “Reconciliation of Non-GAAP EPS to GAAP EPS” shown in Cooper’s earnings release dated 12/6/12
(2) Defined as cash from operating activities less capital expenditures adjusted for insurance recoveries and acquisition costs
(3) Independent Market Research/Management Estimates

Company Overview

The Cooper Companies, Inc. (“Cooper”) is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women’s health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has approximately 7,800 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.

The Cooper Companies
A Quality of Life Company™

- Founded in 1958 and incorporated in 1980
- Operates as a holding company with two business units – exceeded $1.4 billion in fiscal 2012 revenue with 53% of revenue generated outside the United States
- Achieved record revenue and earnings in fiscal 2012
- 13 consecutive years of revenue growth
- Outperformed the S&P 500 Index over a one, three, five and ten year time horizon

CooperVision
Live Brightly.

- 82% of Cooper revenue – exceeded $1.1 billion in fiscal 2012 revenue
- 3rd largest manufacturer of soft contact lenses with approx. 17% global market share and one of the most respected global brands in the business (3)
- Provides best-in-class products competing in all major modalities and materials, including advanced silicone hydrogels. Maintains one of the industry’s largest contact lens portfolios including spherical lenses (to correct common visual defects), toric lenses (to correct astigmatism), multifocal lenses (for presbyopia) and cosmetic lenses.

CooperSurgical
Keeping you at the forefront of women’s healthcare™

- 18% of Cooper revenue – exceeded $255 million in fiscal 2012 revenue
- Focuses on driving enhanced medical outcomes in the women’s healthcare segment through advanced, clinically relevant and procedure-based solutions and services
- Completed over 30 acquisitions since founding in 1990, resulting in 19 core product categories with over 600 products for use in hospitals, women’s health clinics, OB/GYN offices and fertility clinics
FINANCIAL PERFORMANCE

Fiscal Year Ending October 31

Revenue (in millions)

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>CooperVision</td>
<td>$188.0</td>
<td>$209.7</td>
<td>$255.9</td>
</tr>
<tr>
<td>CooperSurgical</td>
<td>$970.5</td>
<td>$1,121.1</td>
<td>$1,189.2</td>
</tr>
</tbody>
</table>

GAAP Earnings Per Share (in dollars)

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$2.43</td>
<td>$3.63</td>
<td>$5.05</td>
</tr>
</tbody>
</table>

Non-GAAP Earnings Per Share (1)

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$3.10</td>
<td>$4.50</td>
<td>$5.16</td>
</tr>
</tbody>
</table>

Free Cash Flow (2)

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$193.9</td>
<td>$232.6</td>
<td>$230.4</td>
</tr>
</tbody>
</table>

The Cooper Companies’ 3-Year Stock Performance Comparison

(10/31/09 - 10/31/12)


- Grow revenue faster than our markets
- Expand CooperVision and CooperSurgical geographically
- Complete strategic acquisitions within CooperVision and CooperSurgical
- Expand operating margin into the mid 20s
- Grow earnings per share faster than revenue
- Generate over $1.3 billion in free cash flow

Contact Information

Kim Duncan
Senior Director, Investor Relations
Lynne Tran
Corporate Communications Manager

The Cooper Companies, Inc.
6140 Stoneridge Mall Road, Suite 590
Pleasanton, CA 94588
Tel: 925-460-3600
Fax: 925-460-3648
info@cooperco.com
ir@cooperco.com
www.coopercos.com

This Fact Sheet contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this Fact Sheet which are not historical facts are forward-looking, including the statements in “Long Term Objectives (2013-2017).” Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing uncertainty and instability of certain European Union countries that could adversely affect our global markets; foreign currency exchange rate and interest rate fluctuations including the risk of further declines in the value of the yen and the euro that would decrease our revenues and earnings; acquisition integration delays or costs or the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period; reduced sales, loss of customers and costs and expenses related to the recall of certain lots of Avaira Toric and Avaira Sphere contact lenses; a major disruption in the operations of our manufacturing, research and development or distribution facilities due to technological problems, natural disasters or other causes; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; legal costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent or other litigation; limitations on sales following new product introductions due to poor market acceptance; new competitors, product innovations or technologies; the impact of acquisitions or divestitures on revenues, earnings or margins; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill; changes in United States and foreign government regulations of the retail optical industry and of the healthcare industry generally; changes in tax laws or their interpretation and changes in effective tax rates; dilution to earnings per share from acquisitions or issuing stock and other events described in our Securities and Exchange Commission filings, including the “Business” and “Risk Factors” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2012, as such Risk Factors may be updated in quarterly filings.

Learn more about The Cooper Companies on your mobile device.

Use a QR reader and the QR code (left) to bring up the website on your mobile device.

(1) See “Reconciliation of Non-GAAP EPS to GAAP EPS” shown in Cooper’s earnings release dated 12/7/10, 12/8/11 and 12/6/12
(2) Defined as cash from operating activities less capital expenditures adjusted for insurance recoveries and acquisition costs